OBJECTIVE: To assess the effect of atomoxetine on ADHD-related executive functions over a 6-month period using the Brown Attention-Deficit Disorder Scale (BADDS) for Adults, a normed, 40-item, self-report scale in a randomized, double-blind, placebo-controlled clinical trial. METHOD: In a randomized, double-blind clinical trial, adults with ADHD received either atomoxetine 25 to 100 mg/day or placebo for 6 months. Patients completed the BADDS to report their current daily functioning in 5 clusters of ADHD-related impairments of executive functioning: (1) Organizing and Activating to Work; (2) Focusing for Tasks; (3) Regulating Alertness and Effort; (4) Modulating Emotions; and (5) Utilizing Working Memory. RESULTS:Mean scores were significantly more improved in the atomoxetine group compared to the placebo group: total score, -27.0 versus -19.0 (p < .001); all 5 cluster scores, p < .01. CONCLUSIONS: Once-daily atomoxetine can improve executive function impairments in adults with ADHD as assessed by the BADDS.
RCT Entities:
OBJECTIVE: To assess the effect of atomoxetine on ADHD-related executive functions over a 6-month period using the Brown Attention-Deficit Disorder Scale (BADDS) for Adults, a normed, 40-item, self-report scale in a randomized, double-blind, placebo-controlled clinical trial. METHOD: In a randomized, double-blind clinical trial, adults with ADHD received either atomoxetine 25 to 100 mg/day or placebo for 6 months. Patients completed the BADDS to report their current daily functioning in 5 clusters of ADHD-related impairments of executive functioning: (1) Organizing and Activating to Work; (2) Focusing for Tasks; (3) Regulating Alertness and Effort; (4) Modulating Emotions; and (5) Utilizing Working Memory. RESULTS: Mean scores were significantly more improved in the atomoxetine group compared to the placebo group: total score, -27.0 versus -19.0 (p < .001); all 5 cluster scores, p < .01. CONCLUSIONS: Once-daily atomoxetine can improve executive function impairments in adults with ADHD as assessed by the BADDS.
Authors: C Neill Epperson; Brian Pittman; Kathryn A Czarkowski; Jeanette Bradley; Donald M Quinlan; Thomas E Brown Journal: Menopause Date: 2011-05 Impact factor: 2.953
Authors: Marios Adamou; Muhammad Arif; Philip Asherson; Tar-Ching Aw; Blanca Bolea; David Coghill; Gísli Guðjónsson; Anne Halmøy; Paul Hodgkins; Ulrich Müller; Mark Pitts; Anna Trakoli; Nerys Williams; Susan Young Journal: BMC Psychiatry Date: 2013-02-17 Impact factor: 3.630
Authors: Narong Maneeton; Benchalak Maneeton; Sirijit Suttajit; Jirayu Reungyos; Manit Srisurapanont; Stephen D Martin Journal: Drug Des Devel Ther Date: 2014-10-03 Impact factor: 4.162
Authors: Termpanit Chalermpalanupap; Becky Kinkead; William T Hu; Markus P Kummer; Thea Hammerschmidt; Michael T Heneka; David Weinshenker; Allan I Levey Journal: Alzheimers Res Ther Date: 2013-04-29 Impact factor: 6.982